Chronic wireless communication between dual-chamber leadless pacemaker devices
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, multicentrická studie
PubMed
39427688
DOI
10.1016/j.hrthm.2024.10.020
PII: S1547-5271(24)03446-5
Knihovny.cz E-zdroje
- Klíčová slova
- Aveir, Dual-chamber, Implant-to-implant communication, Leadless pacemaker, i2i,
- MeSH
- atrioventrikulární blokáda * terapie patofyziologie MeSH
- bezdrátová technologie * přístrojové vybavení MeSH
- design vybavení MeSH
- kardiostimulace umělá * metody MeSH
- kardiostimulátor * MeSH
- lidé středního věku MeSH
- lidé MeSH
- následné studie MeSH
- prospektivní studie MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
BACKGROUND: Aveir DR (Abbott, Abbott Park, IL) is a dual-chamber leadless pacemaker (LP) system with distinct atrial and ventricular LPs (ALP, VLP) that communicate wirelessly to deliver atrioventricular synchronous pacing. Success rates of these implant-to-implant (i2i) transmissions have not been systematically evaluated. OBJECTIVE: This study aims to evaluate chronic i2i success rates in a clinical setting. METHODS: Patients meeting standard dual-chamber pacing indications were enrolled and implanted with dual-chamber LP systems as part of a prospective international clinical trial (Aveir DR i2i Study). The percent of successful i2i transmissions from ALP-to-VLP (A-to-V) and VLP-to-ALP (V-to-A) were interrogated from LPs in de novo patients using the device programmer at implant, discharge, and at 1, 3, and 6 months postimplant (1M, 3M, 6M). RESULTS: A total of 399 patients completed device implant and i2i diagnostic interrogation (62% male; age 69 years; 65% sinus node dysfunction, 32% atrioventricular [AV] block). Median A-to-V and V-to-A i2i success rates exceeded 90% of beats at all time-points from implant to 6M. The minority of patients with A-to-V or V-to-A i2i success in <70% of beats at implant (A-to-V: 19% of patients, V-to-A: 31% of patients) showed roughly 40% improvement by 1M, with this minority dropping to roughly 5% of patients by 6M. Improvement in i2i communication success may be attributed to reprogramming of i2i setting levels, natural changes in dominant posture, and device stabilization. CONCLUSION: Wireless implant-to-implant communication in the new dual-chamber leadless pacemaker system demonstrated successful transmissions in >90% of beats throughout the 6-month evaluation period. Communication success improved significantly over time postimplant for specific subgroups. CLINICAL TRIAL REGISTRATION: Aveir DR i2i Study, ClinicalTrials.gov ID NCT05252702.
Amsterdam UMC Amsterdam The Netherlands
CHRU Albert Michallon Grenoble France
Cleveland Clinic Foundation Cleveland Ohio
Foothills Medical Centre Calgary Alberta Canada
Heart Center Leipzig GmbH Leipzig Germany
HonorHealth Cardiac Arrhythmia Group Scottsdale Arizona
Mount Sinai Fuster Heart Hospital New York New York
Na Homolce Hospital Prague Czech Republic
San Rossore Private Hospital and Medical Center Pisa Italy
Texas Cardiac Arrhythmia Institute Austin Texas
Tokyo Women's Medical University Tokyo Japan
Weill Cornell Medicine New York Presbyterian Hospital New York New York
Citace poskytuje Crossref.org
ClinicalTrials.gov
NCT05252702